A number of research firms have changed their ratings and price targets for Mylan N.V. (NASDAQ: MYL):

  • 8/10/2017 – Mylan N.V. had its “sector perform” rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $32.00 price target on the stock, down previously from $33.00.
  • 8/10/2017 – Mylan N.V. had its “outperform” rating reaffirmed by analysts at BMO Capital Markets. They now have a $45.00 price target on the stock, down previously from $50.00.
  • 8/10/2017 – Mylan N.V. had its “buy” rating reaffirmed by analysts at UBS AG. They now have a $46.00 price target on the stock, down previously from $50.00.
  • 8/9/2017 – Mylan N.V. was given a new $30.00 price target on by analysts at Wells Fargo & Company. They now have a “hold” rating on the stock.
  • 8/9/2017 – Mylan N.V. was given a new $34.00 price target on by analysts at Cantor Fitzgerald. They now have a “hold” rating on the stock.
  • 8/9/2017 – Mylan N.V. had its “hold” rating reaffirmed by analysts at Cowen and Company. They now have a $30.00 price target on the stock, down previously from $43.00.
  • 8/7/2017 – Mylan N.V. had its price target lowered by analysts at Morgan Stanley from $52.00 to $36.00. They now have an “equal weight” rating on the stock.
  • 8/5/2017 – Mylan N.V. was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 8/4/2017 – Mylan N.V. had its “hold” rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $33.00 price target on the stock, down previously from $41.00.
  • 8/3/2017 – Mylan N.V. had its “hold” rating reaffirmed by analysts at Cowen and Company. They now have a $43.00 price target on the stock.
  • 8/1/2017 – Mylan N.V. was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Mylan expects new product launches in the generics segment will propel the top-line. The FDA Oncologic Drugs Advisory Committee (ODAC) recently unanimously recommended approval of Mylan's biosimilar version of breast cancer drug Herceptin. Shares of Mylan have performed better than the industry so far in 2017. However, EpiPen woes continue as sales declined due to increased competition and entry of generics should impact sales. Pricing continues to impact results and the company projects mid-single digit price erosion globally for the year. In addition, Mylan received a complete response letter from the FDA regarding its ANDA for the generic version of asthma drug Advair Diskus. In Apr 2017, Mylan received a warning letter from the FDA for its manufacturing facility in India. The FDA cited significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals in the warning letter.”
  • 7/16/2017 – Mylan N.V. was given a new $41.00 price target on by analysts at Royal Bank Of Canada. They now have a “hold” rating on the stock.
  • 6/22/2017 – Mylan N.V. was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 6/20/2017 – Mylan N.V. was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Mylan’s EpiPen woes continues as sales of the product declined due to increased competition and entry of generics. Pricing continues to impact results and the company projects mid-single digit price erosion globally for the year. In addition, Mylan received a complete response letter from the FDA regarding its ANDA for the generic version of asthma drug Advair Diskus. In Apr 2017, Mylan received a warning letter from the FDA for its manufacturing facility in India. The FDA cited significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals in the warning letter. The violations relate to the agency’s inspection in Sep 2016 and even though the company had responded to the same, the agency deemed them inadequate. Nevertheless, shares of Mylan have performed better than the industry so far in 2017. New product launches in the generics segmnet should help the company combat EpiPen decline.”
  • 6/16/2017 – Mylan N.V. is now covered by analysts at Cantor Fitzgerald. They set a “neutral” rating and a $41.00 price target on the stock.
  • 6/16/2017 – Mylan N.V. was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 6/14/2017 – Mylan N.V. was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 6/13/2017 – Mylan N.V. had its “hold” rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $41.00 price target on the stock.

Mylan N.V. (NASDAQ:MYL) traded down 1.95% during mid-day trading on Friday, reaching $31.66. The company’s stock had a trading volume of 1,793,683 shares. Mylan N.V. has a 12-month low of $29.58 and a 12-month high of $49.42. The firm has a market cap of $16.94 billion, a PE ratio of 25.59 and a beta of 1.27. The company has a 50-day moving average price of $37.57 and a 200-day moving average price of $39.05.

Mylan N.V. (NASDAQ:MYL) last released its quarterly earnings results on Wednesday, August 9th. The company reported $1.10 earnings per share for the quarter, missing the consensus estimate of $1.18 by $0.08. The firm had revenue of $2.96 billion for the quarter, compared to the consensus estimate of $3 billion. Mylan N.V. had a net margin of 5.51% and a return on equity of 22.42%. Mylan N.V.’s quarterly revenue was up 15.7% compared to the same quarter last year. During the same period in the previous year, the company earned $1.16 earnings per share. On average, equities research analysts expect that Mylan N.V. will post $4.68 earnings per share for the current year.

In other news, President Rajiv Malik sold 25,000 shares of the company’s stock in a transaction on Friday, June 9th. The stock was sold at an average price of $40.00, for a total value of $1,000,000.00. Following the completion of the sale, the president now directly owns 799,855 shares in the company, valued at approximately $31,994,200. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Anthony Mauro sold 10,000 shares of the company’s stock in a transaction on Friday, June 9th. The stock was sold at an average price of $40.00, for a total value of $400,000.00. Following the completion of the sale, the insider now owns 140,653 shares of the company’s stock, valued at $5,626,120. The disclosure for this sale can be found here. 0.69% of the stock is owned by corporate insiders.

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.

Receive News & Ratings for Mylan NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan NV and related companies with Analyst Ratings Network's FREE daily email newsletter.